Compare
OSR Health, Inc. vs QHSLab, Inc. vs Nuo Therapeutics, Inc. vs Femasys Inc
| Latest fiscal year | OSR Health, Inc. OSRH | QHSLab, Inc. USAQ | Nuo Therapeutics, Inc. AURX | Femasys Inc FEMY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.91M | $2.69M | $3.31M | $2.29M |
| Revenue growth (YoY) | -17.7% | +26.3% | +142.7% | +40.8% |
| Gross margin | 20.4% | 67.3% | 66.9% | 62.0% (computed) |
| Operating margin | -631.0% | 4.9% | -76.0% | -767.0% |
| Net margin | -931.2% | 17.0% | -75.8% | -812.3% |
| Net income | -$27.06M | $457.4K | -$2.51M | -$18.63M |
| EPS (Diluted) | -$0.80 | $0.02 | n/a | -$0.47 |
| Operating cash flow | -$4.33M | $178.1K | -$865.0K | -$18.69M |
| Free cash flow | n/a | n/a | -$1.14M | -$19.22M |
| Cash & equivalents | $1.70M | $636.2K | $548.9K | $9.27M |
| Total assets | $171.24M | $2.17M | $1.85M | $20.72M |
| Total liabilities | $44.20M | $546.1K | $2.80M | $14.85M |
| Shareholders' equity | $127.04M | $1.62M | -$956.6K | $5.87M |
| Return on year-end equity | -21.3% | 28.1% | n/a | -317.4% |
| Shares outstanding | 26.60M | 15.03M | 48.18M | 59.60M |
Revenue, most recent five fiscal years
| Fiscal year | OSR Health, Inc. | QHSLab, Inc. | Nuo Therapeutics, Inc. | Femasys Inc |
|---|---|---|---|---|
| Latest | $2.91M Ended 2025-12-31 | $2.69M Ended 2025-12-31 | $3.31M Ended 2025-12-31 | $2.29M Ended 2025-12-31 |
| 1 year earlier | $3.53M Ended 2024-12-31 | $2.13M Ended 2024-12-31 | $1.37M Ended 2024-12-31 | $1.63M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.41M Ended 2023-12-31 | $608.5K Ended 2023-12-31 | $1.07M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.24M Ended 2022-12-31 | $112.2K Ended 2022-12-31 | $1.21M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.41M Ended 2021-12-31 | $0 Ended 2021-12-31 | $1.18M Ended 2021-12-31 |